The US FDA Lifts its Clinical Hold on Innate Pharma’s Clinical Evaluation of Lacutamab to Treat Sézary Syndrome
Shots:
- The company has reported that the US FDA has lifted the partial clinical hold placed on the IND for lacutamab earlier in Oct 2023
- The US FDA placed a partial clinical hold on the (TELLOMAK) trial due to the death of a patients affected by Sézary Syndrome, the death was initially considered due to hemophagocytic lymphohistiocytosis (HLH). The hold was later lifted based on Innate’s review along with a committee of experts, which depicted the death to be related to an aggressive disease progression & lacutamab unrelated
- Lacutamab is an anti-KIR3DL2 humanized cytotoxivity-inducing antibody currently being evaluated in trials for the treatment of cutaneous T-cell lymphoma (CTCL) & peripheral T cell lymphoma (PTCL)
Ref: Innate Pharma | Image: Innate Pharma
Related News:- Innate Pharma Reports Results from the P-II Study (TELLOMAK) of Lacutamab for Sézary Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
